Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)
Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –
Fennec Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Fennec Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was 3.1%. For fiscal 2025 it was -21.8%, against -0.9% the year before. The highest annual figure on record is -0.9% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -21.8% | −20.9 |
| FY2024 | Dec 31, 2024 | -0.9% | +74.6 |
| FY2023 | Dec 31, 2023 | -75.5% | +1469.4 |
| FY2022 | Dec 31, 2022 | -1544.9% | +7509.6 |
| FY2020 | Dec 31, 2020 | -9054.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 23.7% | +28.8 |
| Q2 FY2026 | Jun 30, 2026 | 11.0% | +43.7 |
| Q1 FY2026 | Mar 31, 2026 | 1.3% | +14.6 |
| Q4 FY2025 | Dec 31, 2025 | -34.7% | −9.7 |
| Q3 FY2025 | Sep 30, 2025 | -5.1% | +77.1 |
| Q2 FY2025 | Jun 30, 2025 | -32.7% | +43.8 |
| Q1 FY2025 | Mar 31, 2025 | -13.3% | −63.9 |
| Q4 FY2024 | Dec 31, 2024 | -25.0% | +2.5 |
| Q3 FY2024 | Sep 30, 2024 | -82.2% | −53.6 |
| Q2 FY2024 | Jun 30, 2024 | -76.5% | +87.3 |
| Q1 FY2024 | Mar 31, 2024 | 50.6% | +411.5 |
| Q4 FY2023 | Dec 31, 2023 | -27.6% | +1591.4 |
| Q3 FY2023 | Sep 30, 2023 | -28.7% | – |
| Q2 FY2023 | Jun 30, 2023 | -163.7% | – |
| Q1 FY2023 | Mar 31, 2023 | -360.9% | – |
| Q4 FY2020 | Dec 31, 2020 | -1619.0% | – |
See a number that looks wrong?